PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using…
Conditions studied
Pulmonary Hypertension
About this study
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.
Primary outcomes
- Time to clinical worsening (Up to 36 months)
- All-cause mortality (Up to 36 months)
Eligibility information
Study locations
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350011 China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.